Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bicara Therapeutics

12.42
-0.9300-6.97%
Post-market: 12.840.4200+3.38%16:22 EDT
Volume:746.12K
Turnover:9.60M
Market Cap:675.84M
PE:-0.69
High:14.04
Open:13.49
Low:12.01
Close:13.35
Loading ...

Bicara Therapeutics Price Target Maintained With a $13.01/Share by Cantor Fitzgerald

Dow Jones
·
13 Mar

Bicara Therapeutics Price Target Maintained With a $31.00/Share by Wedbush

Dow Jones
·
13 Feb

Bicara Therapeutics Inc - Phase 2/3 Trial to Enroll Approximately 650 Patients

THOMSON REUTERS
·
12 Feb

Bicara Therapeutics Announces First Patients Enrolled in Fortifi-Hn01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

THOMSON REUTERS
·
12 Feb

Bicara Therapeutics Inc - Primary Endpoints Include Overall Response Rate and Survival

THOMSON REUTERS
·
12 Feb

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

GlobeNewswire
·
12 Feb

Bicara Therapeutics Initiated at Outperform by Wedbush

Dow Jones
·
06 Feb

Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target

MT Newswires Live
·
06 Feb

Bicara Therapeutics initiated with an Outperform at Wedbush

TIPRANKS
·
06 Feb

Bicara Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $31

THOMSON REUTERS
·
06 Feb

Promising Clinical Trial Results Drive Buy Rating for Bicara Therapeutics

TIPRANKS
·
28 Jan

Bicara presents data from Phase 1/1b dose expansion cohort of ficerafusp alfa

TIPRANKS
·
27 Jan

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

GlobeNewswire
·
27 Jan

Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
27 Jan

Stifel Nicolaus Sticks to Their Buy Rating for Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
27 Jan

Third Rock-backed Maze Therapeutics reveals profit in US IPO filing

Reuters
·
08 Jan